Want to see CRBU full AI Analyst Report?
CRBU Stock Chart & Stats
$1.57
$0.05(3.50%)
At close: 4:00 PM EDT
$1.57
$0.05(3.50%)
Day’s Range― - ―
52-Week Range$1.38 - $3.54
Previous CloseN/A
Volume203.30K
Average Volume (3M)1.20M
Market Cap
$168.61M
Enterprise Value$91.46
Total Cash (Recent Filing)$117.63M
Total Debt (Recent Filing)$26.95M
Price to Earnings (P/E)―
Beta2.52
Next Earnings
Mar 11, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.42
Shares Outstanding99,180,570
10 Day Avg. Volume1,354,975
30 Day Avg. Volume1,199,069
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)1.22
Price to Sales (P/S)13.31
P/FCF Ratio-1.32
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$8.00Price Target Upside409.55% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.19
Revenue Forecast (FY)$25.65M
Bulls Say, Bears Say
Bulls Say
Strong Early Clinical EfficacyRobust Phase 1 response rates across vispa-cel and CB-011 provide durable evidence of clinical activity for Caribou’s allogeneic programs. High ORR/CR and MRD-negativity imply meaningful therapeutic potential and strengthen long-term development and partner interest for off-the-shelf cell therapies.
Regulatory Acceleration (RMAT)RMAT designation for CB-011 signals faster FDA engagement and potential expedited review pathways. This structural regulatory advantage can shorten development timelines, improve trial-to-approval probability, and enhance strategic optionality versus programs without such designations.
Modest Financial LeverageA low debt-to-equity ratio reduces near-term solvency and refinancing pressure relative to many early-stage biotech peers. Modest formal leverage preserves operational flexibility and lowers immediate bankruptcy risk while clinical programs progress and external funding is secured.
Bears Say
High Cash BurnSustained negative operating and free cash flow near -$100M TTM materially erodes liquidity and forces recurring capital raises or partner funding. Persistent cash burn increases dilution risk, constrains investment pacing, and heightens financing vulnerability if clinical timelines extend.
Volatile, Declining Revenue And Large LossesRevenue has materially declined and is volatile while operating losses remain large (TTM EBIT ≈ -$132M). Although gross margin is high, the current cost base and negative profitability indicate the business model depends on continued partner payments or new funding to sustain development activities.
Shrinking Equity CushionA sharply reduced equity base cuts the company’s financial buffer against prolonged losses and increases the likelihood of dilution or less favorable financing terms. Lower equity weakens resilience to setbacks and reduces strategic flexibility during extended clinical development.
Caribou Biosciences News
CRBU FAQ
What was Caribou Biosciences’s price range in the past 12 months?
Caribou Biosciences lowest stock price was $1.38 and its highest was $3.54 in the past 12 months.
What is Caribou Biosciences’s market cap?
Caribou Biosciences’s market cap is $168.61M.
When is Caribou Biosciences’s upcoming earnings report date?
Caribou Biosciences’s upcoming earnings report date is Mar 11, 2027 which is in 209 days.
How were Caribou Biosciences’s earnings last quarter?
Caribou Biosciences released its earnings results on Aug 13, 2026. The company reported -$0.24 earnings per share for the quarter, beating the consensus estimate of -$0.324 by $0.084.
Is Caribou Biosciences overvalued?
According to Wall Street analysts Caribou Biosciences’s price is currently Undervalued.
Does Caribou Biosciences pay dividends?
Caribou Biosciences does not currently pay dividends.
What is Caribou Biosciences’s EPS estimate?
Caribou Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Caribou Biosciences have?
Caribou Biosciences has 99,180,570 shares outstanding.
What happened to Caribou Biosciences’s price movement after its last earnings report?
Caribou Biosciences reported an EPS of -$0.24 in its last earnings report, beating expectations of -$0.324. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Caribou Biosciences?
Currently, no hedge funds are holding shares in CRBU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Caribou Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.00 (409.55% Upside)
$8.00 (409.55% Upside)
Hedge Fund Trend
Decreased
By 68.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 2.2%
Last 30 Days ▼ 2.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
41.00%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-45.55%
Trailing 12-Months
Company Description
Caribou Biosciences
Caribou Biosciences, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to pioneering genome-edited allogeneic cell therapies. These cutting-edge treatments are engineered to address both hematologic malignancies (blood cancers) and solid tumors, serving patients across the United States and internationally. Among its primary therapeutic candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy currently undergoing Phase 1 clinical trials for relapsed or refractory B cell non-Hodgkin lymphoma, and CB-011, an allogeneic anti-BCMA CAR-T cell therapy targeting relapsed or refractory multiple myeloma. Caribou Biosciences is additionally developing CB-012, an allogeneic anti-CD371 CAR-T cell therapy for relapsed or refractory acute myeloid leukemia, along with CB-020, an allogeneic CAR-NK cell therapy aimed at solid tumors. The company also maintains a collaborative agreement with AbbVie Manufacturing Management Unlimited Company for the joint advancement of CAR-T cell therapies. Founded in 2011, Caribou Biosciences' headquarters are located in Berkeley, California.
CRBU Stock 12 Month Forecast
Average Price Target
$8.00
▲(409.55% Upside)
Technical Analysis
Ownership Overview
4.66% Insiders
5.81% Mutual Funds
5.58% Other Institutional Investors
71.13% Public Companies and
Individual Investors